Chinese Journal of Antituberculosis ›› 2020, Vol. 42 ›› Issue (12): 1329-1332.doi: 10.3969/j.issn.1000-6621.2020.12.015
• Original Articles • Previous Articles Next Articles
LI Meng, LU Li-ping, JIANG Qi, HONG Jian-jun, GAO Qian, YANG Chong-guang(), GUO Xiao-qin()
Received:
2020-05-27
Online:
2020-12-10
Published:
2020-12-24
Contact:
YANG Chong-guang,GUO Xiao-qin
E-mail:chongguang.yang@yale.edu;guoxiaoqin1102@163.com
LI Meng, LU Li-ping, JIANG Qi, HONG Jian-jun, GAO Qian, YANG Chong-guang, GUO Xiao-qin. Analysis of the types and expense of therapeutic drugs for pulmonary tuberculosis in Songjiang District of Shanghai[J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1329-1332. doi: 10.3969/j.issn.1000-6621.2020.12.015
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2020.12.015
药品类别 | 使用药品例数 | 占比(%) | 每例患者的药品费用[元,M(Q1,Q3)] | 构成比(%) |
---|---|---|---|---|
一线抗结核药品 | 248 | 100.0 | 462.4(368.9,591.8) | 12.8(8.5,18.6) |
二线抗结核药品 | 98 | 39.5 | 364.1(133.0,992.6) | 8.2(3.6,16.9) |
保肝药 | 248 | 100.0 | 2263.5(1620.0,2961.0) | 62.1(47.5,74.6) |
抗生素 | 100 | 40.3 | 597.5(239.0,980.5) | 9.7(5.3,17.2) |
中草药/中成药 | 144 | 58.1 | 757.2(255.2,1853.1) | 14.8(5.9,28.9) |
免疫调节剂 | 67 | 27.0 | 432.0(21.0,686.0) | 8.6(0.7,14.0) |
并发症用药 | 84 | 33.9 | 91.7(38.3,342.2) | 2.3(1.0,7.9) |
其他 | 31 | 12.5 | 349.0(125.5,737.2) | 2.9(1.5,6.1) |
合计 | 248 | 100.0 | 3719.0(2483.4,5634.9) | - |
药品类别 | 使用药品例数 | 占比(%) | 每例患者的药品费用[元,M(Q1,Q3)] | 构成比(%) |
---|---|---|---|---|
一线抗结核药品 | 248 | 100.0 | 462.4(368.9,591.8) | 12.8(8.5,18.6) |
二线抗结核药品 | 98 | 39.5 | 364.1(133.0,992.6) | 8.2(3.6,16.9) |
保肝药 | 248 | 100.0 | 2263.5(1620.0,2961.0) | 62.1(47.5,74.6) |
抗生素 | 100 | 40.3 | 597.5(239.0,980.5) | 9.7(5.3,17.2) |
中草药/中成药 | 144 | 58.1 | 757.2(255.2,1853.1) | 14.8(5.9,28.9) |
免疫调节剂 | 67 | 27.0 | 432.0(21.0,686.0) | 8.6(0.7,14.0) |
并发症用药 | 84 | 33.9 | 91.7(38.3,342.2) | 2.3(1.0,7.9) |
其他 | 31 | 12.5 | 349.0(125.5,737.2) | 2.9(1.5,6.1) |
合计 | 248 | 100.0 | 3719.0(2483.4,5634.9) | - |
[5] | 童维佳, 王洁, 李璧辰, 等. 我院2016年30例结核病初治患者用药情况及减轻患者负担的探讨. 中国药物与临床, 2017,17(10):1523-1525. doi: 10.11655/zgywylc2017.10.049. |
[6] | Zhou C, Long Q, Chen J, et al. Factors that determine catastrophic expenditure for tuberculosis care: a patient survey in China. Infect Dis Poverty, 2016,5:6. doi: 10.1186/s40249-016-0100-6. |
[7] |
Pandey A, Ploubidis GB, Clarke L, et al. Trends in catastrophic health expenditure in India: 1993 to 2014. Bull World Health Organ, 2018,96(1):18-28. doi: 10.2471/BLT.17.191759.
URL pmid: 29403097 |
[8] | World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization, 2017. |
[9] | Floyd K, Glaziou P, Houben R, et al. Global tuberculosis targets and milestones set for 2016—2035: definition and rationale. Int J Tuberc Lung Dis, 2018,22(7):723-730. doi: 10.5588/ijtld.17.0835. |
[10] | 上海市卫生局. 上海市活动性肺结核病二线抗结核药物及护肝药物减免治疗项目实施方案. 沪疾控传(2008)112号.2008-10-06. |
[1] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[2] | 郑亦慧. 上海市普陀区非户籍人口结核病经济负担研究. 上海:复旦大学, 2011. |
[11] | 姜伟, 仇桑桑, 陆慧, 等. 江苏省张家港市肺结核患者疾病经济负担及影响因素分析. 中国防痨杂志, 2014,36(2):98-103. doi: 10.3969/j.issn.1000-662l.2014.02.004. |
[12] | 刘艳, 徐彩红, 王振宇, 等. 我国结核病定点医院肺结核患者家庭经济负担现况调查. 中华流行病学杂志, 2019,40(5):559-564. doi: 10.3760/cma.j.issn.0254-6450.2019.05.013. |
[13] | 王超, 郭立杰, 张海丛, 等. 初治结核病患者预防使用保肝药物对药物性肝损伤的价值研究. 临床误诊误治, 2019,32(9):21-26. doi: 10.3969/j.issn.1002-3429.2019.09.007. |
[14] | Zhang S, Pan H, Peng X, et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial. J Gastroenterol Hepatol, 2016,31(2):409-416. doi: 10.1111/jgh.13070. |
[3] | 黄小敏. 肺结核门诊费用纳入新型农村合作医疗补偿机制研究. 济南:山东大学, 2012. |
[4] | 蒙志好, 李勇, 张锡贵. 肺结核患者住院费用调查研究. 中国医院统计, 2006,13(4):333-335. doi: 10.3969/j.issn.1006-5253.2006.04.011. |
[5] | 童维佳, 王洁, 李璧辰, 等. 我院2016年30例结核病初治患者用药情况及减轻患者负担的探讨. 中国药物与临床, 2017,17(10):1523-1525. doi: 10.11655/zgywylc2017.10.049. |
[15] | Saito Z, Kaneko Y, Kinoshita A, et al. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis. BMC Infect Dis, 2016,16(1):668. doi: 10.1186/s12879-016-2000-6. |
[16] | 赵晶. 抗结核药肝损害前后应用保肝药的效果研究. 心理医生, 2019,25(2):129-130. |
[6] | Zhou C, Long Q, Chen J, et al. Factors that determine catastrophic expenditure for tuberculosis care: a patient survey in China. Infect Dis Poverty, 2016,5:6. doi: 10.1186/s40249-016-0100-6. |
[17] | 王建云, 周莹荃, 贾忠, 等. 不同药物预防抗结核药物致肝损害的疗效比较. 西部中医药, 2017,30(6):66-68. doi: 10.3969/j.issn.1004-6852.2017.06.023. |
[7] |
Pandey A, Ploubidis GB, Clarke L, et al. Trends in catastrophic health expenditure in India: 1993 to 2014. Bull World Health Organ, 2018,96(1):18-28. doi: 10.2471/BLT.17.191759.
URL pmid: 29403097 |
[18] | Chen Y, Ye P, Ren C, et al. Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China. Open Med(Wars), 2018,13:53-63. doi: 10.1515/med-2018-0010. |
[19] | 覃红娟, 张宏, 谭守勇. 免疫调节剂在预防HBsAg阳性肺结核患者抗结核药物性肝损伤的效果观察. 岭南急诊医学杂志, 2017,22(3):278-279. doi: 10.3969/j.issn.1671-301X.2017.03.029. |
[20] | 吕振东. 研究免疫调节剂胸腺肽联合抗结核药物治疗耐多药肺结核的效果. 中国保健营养, 2016,26(11):214-215. |
[8] | World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization, 2017. |
[9] | Floyd K, Glaziou P, Houben R, et al. Global tuberculosis targets and milestones set for 2016—2035: definition and rationale. Int J Tuberc Lung Dis, 2018,22(7):723-730. doi: 10.5588/ijtld.17.0835. |
[10] | 上海市卫生局. 上海市活动性肺结核病二线抗结核药物及护肝药物减免治疗项目实施方案. 沪疾控传(2008)112号.2008-10-06. |
[11] | 姜伟, 仇桑桑, 陆慧, 等. 江苏省张家港市肺结核患者疾病经济负担及影响因素分析. 中国防痨杂志, 2014,36(2):98-103. doi: 10.3969/j.issn.1000-662l.2014.02.004. |
[12] | 刘艳, 徐彩红, 王振宇, 等. 我国结核病定点医院肺结核患者家庭经济负担现况调查. 中华流行病学杂志, 2019,40(5):559-564. doi: 10.3760/cma.j.issn.0254-6450.2019.05.013. |
[13] | 王超, 郭立杰, 张海丛, 等. 初治结核病患者预防使用保肝药物对药物性肝损伤的价值研究. 临床误诊误治, 2019,32(9):21-26. doi: 10.3969/j.issn.1002-3429.2019.09.007. |
[14] | Zhang S, Pan H, Peng X, et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial. J Gastroenterol Hepatol, 2016,31(2):409-416. doi: 10.1111/jgh.13070. |
[15] | Saito Z, Kaneko Y, Kinoshita A, et al. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis. BMC Infect Dis, 2016,16(1):668. doi: 10.1186/s12879-016-2000-6. |
[16] | 赵晶. 抗结核药肝损害前后应用保肝药的效果研究. 心理医生, 2019,25(2):129-130. |
[17] | 王建云, 周莹荃, 贾忠, 等. 不同药物预防抗结核药物致肝损害的疗效比较. 西部中医药, 2017,30(6):66-68. doi: 10.3969/j.issn.1004-6852.2017.06.023. |
[18] | Chen Y, Ye P, Ren C, et al. Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China. Open Med(Wars), 2018,13:53-63. doi: 10.1515/med-2018-0010. |
[19] | 覃红娟, 张宏, 谭守勇. 免疫调节剂在预防HBsAg阳性肺结核患者抗结核药物性肝损伤的效果观察. 岭南急诊医学杂志, 2017,22(3):278-279. doi: 10.3969/j.issn.1671-301X.2017.03.029. |
[20] | 吕振东. 研究免疫调节剂胸腺肽联合抗结核药物治疗耐多药肺结核的效果. 中国保健营养, 2016,26(11):214-215. |
[1] | LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936. |
[2] | DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961. |
[3] | CHEN Yu-mei, LUO Xing-xiong, CHEN Cheng-jiang, SU Ping, WANG Chun-lei.. Analysis of the service capability in city/county tuberculosis designated hospital in Hainan [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 992-993. |
[4] | SUN Hai-yan, LI Shuo, WANG Zhong-dong, REN Zhi-sheng, SONG Song, XUE Bai, ZHANG Hua-qiang, DAI Xiao-qi. Characteristics of the tuberculosis epidemic in schools in Qingdao in 2010—2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 994-997. |
[5] | ZHONG Qian-hong, MA Xiao-hui, LIN Zhi-hao, LI Yi, ZHOU Jie, DENG Dong-hua, DENG Ci-xi, LIANG Xiao-min. Evaluation of the application of Foshan Tuberculosis Surveillance and Management Platform in tuberculosis prevention and treatment [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 653-656. |
[6] | BAO Xun-di, JIANG Yue, LIANG Suo, CHENG Hong-yan, XIA Guang-xiu, WANG Chao, YE Qian, WANG Shu, WANG Qing. Analysis of the clinical isolation rate, population distribution and drug resistance of non-tuberculous mycobacteria in Anhui [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 718-724. |
[7] | LIANG Xiao-yan, LIN Mei, LIANG Da-bin, LAN Ru-shu, QIN Hui-fang, YE Jing, HUANG Li-wen. Drug resistance and genotypic characteristics of multidrug-resistant Mycobacterium tuberculosis in Guangxi Zhuang Autonomous Region [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 578-582. |
[8] | LAI Keng, LEI Yu, DU Yu-hua, WU Gui-feng, XIE Wei, SHEN Hong-cheng, ZHONG Zhi-qing, LI Tie-gang. Spatial-temporal analysis on tuberculosis among students in Guangzhou City during 2014-2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 590-596. |
[9] | ZHANG Jing, CHEN Xi, WANG Bin, FU Lei, LU Yu, CHEN Xiao-you. Establishment of modified propidium monoazide (PMAxx)-quantitative PCR assay and its application for identification of antituberculosis drug activity [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 472-480. |
[10] | SHEN Hong-cheng,DU Yu-hua,WU Gui-feng,LEI Yu,LI Tie-gang,LIU Jian-xiong. Epidemiological characteristics of newly reported pulmonary tuberculosis from 2008 to 2018 in Guangzhou [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 322-326. |
[11] | QIN Nan,XU Chun-ze,GUAN Ying,LU Li-ping,WANG Wei-bing,JIANG Yong-gen. The characteristics and analysis of influencing factors of tuberculosis registered dead patients in Songjiang City, Shanghai [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 345-352. |
[12] | GAO Tian-hui,SHU Wei,GAO Jing-tao,LU Yu,LI Qi. Analysis of clarithromycin resistance and its influencing factors in 254 patients with drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 259-265. |
[13] | CHEN Hao,WU Nan-nan,HU Wen-hui,YANG Zhong-jin. Research progress of new targets for antituberculosis agents [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 286-292. |
[14] | WANG Jing,ZHANG Meng,HE Jian-qing. Clostridium difficile-associated diarrhea caused by anti-tuberculosis drugs: a case report and literature review [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 293-296. |
[15] | QIU Lei,ZHANG Shao-yan,GUO Xiao-yan,FU Ji-you,TIAN Li-ming,ZHANG Hui-yong,LU Zhen-hui. Clinical value of chemotherapy regimen and Qinbudan tablet on the retreatment of retreated smear-positive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 108-114. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||